Table 1 Subject demographics and baseline characteristics
Early treatment group (n = 65) | Later treatment group (n = 31) | t/Z/χ2 | P value | |
|---|---|---|---|---|
Subject demographics (n = 96) | ||||
Gender (male/female) | 65 (29/36) | 31 (18/13) | 1.52 | 0.218 |
Age at start treatment (years) | 0.50 (0.42) | 1.42 (0.67) | 7.91 | < 0.001 |
Genotype (deletion/nondeletion/unknown) | 65 (42/15/8) | 31 (21/7/3) | 0.16 | 0.923 |
Auxological parameters (n = 96) | ||||
Height/length SDS | −1.10 ± 1.36 | −1.42 ± 1.54 | 1.04 | 0.300 |
Weight SDS | −1.81 ± 1.02 | −1.24 ± 1.12 | 2.46 | 0.016 |
Weight for height SDS | −1.58 (2.26) | −0.94 (1.36) | 1.02 | 0.306 |
Carbohydrate metabolism (n = 32) | ||||
Gender (male/female) | 19 (7/12) | 13 (8/5) | 0.280* | |
Genotype (deletion/nondeletion/unknown) | 19 (15/3/1) | 13 (10/3/0) | 0.96 | 0.808 |
Fasting insulin (μIU/mL) | 3.50 (2.38) | 3.50 (3.29) | 0.82 | 0.426 |
Fasting glucose (mmol/L) | 4.57 (0.19) | 4.57 (0.95) | 0.39 | 0.705 |
HOMA-IR | 0.71 (0.53) | 0.71 (0.83) | 0.68 | 0.520 |